Pharmaceuticals

Bright Green

Bright Green released FY2024 Q3 earnings on November 19 (EST) with actual revenue of 0 USD and EPS of -0.0057 USD

Bright Green released FY2024 Cumulative 3Q Earnings on November 19 (EST), Revenue: 0, EPS: -0.0184

Bright Green Corp applies to produce 22 controlled substances

Netcapital

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

Agape ATP

PicoCELA

Tradr 2X Long QBTS Daily ETF

Co-Diagnostics

NewGenIvf

Akanda

Defiance Daily Target 2X Long RGTI ETF

Tradr 2X Long RGTI Daily ETF

BGXXQ

BGXX

Green Bridge Metals Reports Visible Copper Sulfide Mineralization in Initial 2026 Titac Drilling, Duluth Complex Minnesota | GBMCF Stock News

StockTitan

BRIGHT GREEN CORPORATION

Green Bridge Metals Reports Visible Copper Sulfide Mineralization in Initial 2026 Titac Drilling, Duluth Complex Minnesota | GBMCF Stock News

SBIO

A recent clinical trial in South San Francisco showed that Brightseed® BioMetaControl significantly improves glycemic control in adults with prediabetes. The randomized, double-blind, placebo-controlled study highlighted the effectiveness of the supplement, which contains natural bioactive compounds N-trans caffeoyltyramine (NCT) and N-trans feruloyltyramine (NFT). The findings were published in the journal Bioactive Compounds in Health and Disease, indicating a positive impact on managing prediabetes.

Unusual Whales

Invesco Biotechnology & Genome ETF

ALPS Medical Breakthrough

First Trust NYSE Arca Biotech Index Fd

iShares Biotechnology ETF

SPDR S&P Biotech

VanEck Biotech ETF

Proshares Ultra Nasdaq Biotech

Clinical trial shows Brightseed® BioMetaControl improves glycemic control in prediabetes. Contains NCT and NFT. Study published in Bioactive Compounds in Health and Disease.

Fort Lauderdale, FL, Sept. 16, 2025 ( GLOBE NEWSWIRE ) -- PharmAGRI Capital Partners today announced its strategic focus on capturing a $10 billion total addressable market ( TAM ) in federal procurement of plant-based prescription drugs currently sourced from foreign manufacturers.

GlobeNewswire

PharmAGRI Capital Partners Targets $10 Billion Federal Procurement Opportunity for Onshored Plant-Based Prescription Drugs Bright Green Corporation "BGXXQ" Q and A

Bright Green Corporation has merged with PharmAGRI Capital Partners, with Lynn Stockwell appointed as CEO and Chairwoman. The merger aims to restore U.S. drug manufacturing sovereignty and will consolidate various licenses and registrations under a court-supervised restructuring. PharmAGRI plans to deploy Tesla robotics for drug manufacturing, enhancing compliance and creating high-wage jobs. The company intends to file for Nasdaq relisting and complete an IPO by the end of 2025, focusing on federal contracts and expanding U.S. pharmaceutical infrastructure.

Bright Green Corporation Merges with PharmAGRI Capital Partners; Lynn Stockwell Appointed CEO and Chairwoman | BGXX Stock News

In Fort Lauderdale, Florida, on February 24, 2025, Bright Green Corporation (OTC: BGXX) revealed a significant development. Lynn Stockwell, representing the Company, has formally requested court approval for the "RSA" Restructuring Security Agreement. The main points of the RSA involve securing fresh equity to fully settle all outstanding debts with authorized claims, ensuring that the Company's existing equity shareholders maintain their ownership stakes without any reduction or dilution.

Bright Green Corp shifts from cannabis to DEA Schedule Controlled Substances, completes restructuring plan, as per RSA agreement, pays creditors in full, retains equity interest, no dilution for shareholders.

On February 24, 2025, in Fort Lauderdale, Florida, Bright Green Corporation (OTC: BGXX) disclosed its proposal for the "RSA" Restructuring Security Agreement through Lynn Stockwell, requesting court approval. This agreement aims to secure fresh equity facilitating full payment to all verified creditors and ensuring existing Company equity shareholders maintain their stake without any dilution or impairment.

Bright Green Corp exits Cannabis, focuses on DEA Controlled Substances post restructuring; creditors to receive full payment. Lynn Stockwell leads RSA for equity retention.

In Fort Lauderdale, Florida, on February 24, 2025, Bright Green Corporation (OTC: BGXX) disclosed that Lynn Stockwell, representing the company, has filed for court approval of the "RSA" Restructuring Security Agreement. The RSA aims to secure fresh equity for the company to settle all outstanding debts to verified creditors entirely. Furthermore, existing equity shareholders of the Company will maintain their ownership stakes without any reduction or dilution.

Bright Green Corporation completes restructuring, exits Cannabis business, opts for DEA Controlled Substances. $XX equity for creditors, shareholders remain unimpaired.

Bright Green Corp (BGXXQ) filed for Chapter 11 bankruptcy on February 22, 2025, in New Mexico, operating as a debtor-in-possession. On March 17, 2025, the company submitted a proposed reorganization plan to the Bankruptcy Court. The approval of the plan and successful restructuring are uncertain, and stakeholders are warned about the speculative nature of trading the company's securities. Year-to-date, the stock has dropped 41.67%, with a current market cap of $7.17M and an average trading volume of 188,037.

Tip Ranks

Bright Green Corp Files for Chapter 11 Bankruptcy

Bright Green(BGXX.US)

Green Bridge Metals Reports Visible Copper Sulfide Mineralization in Initial 2026 Titac Drilling, Duluth Complex Minnesota | GBMCF Stock News

Clinical trial shows Brightseed® BioMetaControl improves glycemic control in prediabetes. Contains NCT and NFT. Study published in Bioactive Compounds in Health and Disease.

PharmAGRI Capital Partners Targets $10 Billion Federal Procurement Opportunity for Onshored Plant-Based Prescription Drugs Bright Green Corporation "BGXXQ" Q and A

Bright Green Corporation Merges with PharmAGRI Capital Partners; Lynn Stockwell Appointed CEO and Chairwoman | BGXX Stock News

Bright Green Corp shifts from cannabis to DEA Schedule Controlled Substances, completes restructuring plan, as per RSA agreement, pays creditors in full, retains equity interest, no dilution for shareholders.

Bright Green Corp exits Cannabis, focuses on DEA Controlled Substances post restructuring; creditors to receive full payment. Lynn Stockwell leads RSA for equity retention.

Bright Green Corporation completes restructuring, exits Cannabis business, opts for DEA Controlled Substances. $XX equity for creditors, shareholders remain unimpaired.

Bright Green Corp Files for Chapter 11 Bankruptcy